

Guideline on the preventive treatment of chronic migraine, chronic tension type headache, hemicrania continua and new daily persistent headache on behalf of the Colombian Association of Neurology

Guía de la Asociación Colombiana de Neurología para el tratamiento preventivo de la migraña crónica, cefalea tipo tensión crónica, hemicránea continua y cefalea diaria persistente de novo

Joe Fernando Muñoz-Cerón (1), Mauricio Rueda Sánchez (2), Oscar Enrique Pradilla-Vesga (3), Michel Volcy (4) Natalia Hernández (5), Sergio Francisco Ramírez (6), Fidel Sobrino (7), Bernardo Uribe (8), Carolina Guerra (9), Juan Diego Jiménez (10), Marta Liliana Ramos (11), Gustavo Pradilla (†) (12), José David Martínez (13), Cesar Daniel Torres (14), Gabriel Torres (15)

SUMMARY

INTRODUCTION: chronic daily headache is a high impact entity in the general population. Although chronic migraine and tension-type headache are the most frequent conditions, it is necessary to consider hemicrania continua and new daily persistent headache as part of the differential diagnoses to perform a correct therapeutic approach.

OBJECTIVE: to make recommendations for the treatment of chronic daily headache of primary origin

METHODOLOGY: The Colombian Association of Neurology, by consensus and Grade methodology (Grading of recommendations, assessment, development and evaluation), presents the recommendations for the preventive treatment of each of the entities of the daily chronic headache of primary origin group.

RESULTS: for the treatment of chronic migraine, the Colombian Association of Neurology recommends onabotulinum toxin A, erenumab, topiramate, flunarizine, amitriptyline, and naratriptan. In chronic tension-type headache the recommended therapeutic options are amitriptyline, imipramine, venlafaxine and mirtazapine. Topiramate, melatonin, and celecoxib for the treatment of hemicrania continua. Options for new daily persistent headache include gabapentin and doxycycline. The recommendations for inpatient treatment of patients with chronic daily headache and the justifications for performing neural blockades as a therapeutic complement are also presented.

CONCLUSION: the therapeutic recommendations for the treatment of chronic daily headache based on consensus methodology and Grade System are presented.

(1) Hospital Universitario Mayor, CIMED - Universidad del Rosario, Clínica Universitaria Colombia, Bogotá, Colombia.

(2) Práctica privada, Bucaramanga, Colombia.

(3) Fundación Oftalmológica de Santander, Clínica Carlos Ardila Lulle, Bucaramanga, Colombia.

(4) Instituto de Dolor de Cabeza y Enfermedades Neurológicas (Indocen), Medellín, Colombia.

(5) Promedan, Neuroclínica, Neuromédica, Medellín, Colombia.

(6) Colsanitas, Hospital San José Infantil, Bogotá, Colombia.

(7) Hospital de Kennedy, Universidad de La Sabana, Bogotá, Colombia.

(8) Universidad de Manizales, Manizales, Colombia.

(9) Clínica Soma, Medellín, Colombia.

(10) Clínica Confamiliar Risaralda, Pereira, Colombia.

(11) Hospital La Samaritana, Bogotá - Colombia.

(12) Universidad Industrial de Santander, Bucaramanga, Colombia.

(13) Clínica Universitaria Bolivariana - IPS Neuromédica, Medellín, Colombia.

(14) Clínica Universitaria Colombia, Bogotá, Colombia.

(15) Universidad de York, York, Reino Unido.

Recibido 9/5/20. Aceptado: 9/5/20.

Correspondencia: Joe Muñoz, jofer482@yahoo.com

KEYWORDS: consensus; chronic daily headache; chronic migraine; chronic tension-type headache; hemicrania continua (MeSH)

RESUMEN

INTRODUCCIÓN: la cefalea crónica diaria es una entidad de alto impacto en la población general. Aunque la migraña crónica y la cefalea tipo tensión son las condiciones más frecuentes, es necesario considerar la hemicránea continua y la cefalea diaria persistente de novo como parte de los diagnósticos diferenciales para realizar un enfoque terapéutico correcto.

OBJETIVO: hacer recomendaciones para el tratamiento de la cefalea crónica diaria de origen primario

METODOLOGÍA: la Asociación Colombiana de Neurología, mediante consenso y metodología Grade (Grading of recommendations, assessment, development and evaluation), presenta las recomendaciones para el tratamiento preventivo de cada una de las entidades del grupo de la cefalea crónica diaria de origen primario.

RESULTADOS: para el tratamiento de la migraña crónica, la Asociación Colombiana de Neurología recomienda onabotulinum toxina A, erenumab, galcanezumab, fremanezumab, topiramato, flunarizina, amitriptilina y nara-triptan. En cefalea tipo tensional crónica las opciones terapéuticas recomendadas son amitriptilina, imipramina, venlafaxina y mirtazapina. Para el tratamiento de la hemicránea continua topiramato, melatonina y celecoxib. Las opciones para cefalea diaria persistente de novo incluyen gabapentin y doxiciclina. Se presentan adicionalmente las recomendaciones para el tratamiento intrahospitalario de los pacientes con cefalea crónica diaria y las justificaciones para la realización de bloqueos neurales como complemento terapéutico.

CONCLUSIÓN: se presentan las recomendaciones terapéuticas para el tratamiento de la cefalea crónica diaria basado en metodología de consenso y sistema Grade.

PALABRAS CLAVE: consenso; cefalea crónica diaria; migraña crónica; cefalea tipo tensión crónica; hemicránea continua (DeCS).

INTRODUCTION

At least 50% of the general population has suffered from headache during the last year (1). Although chronic tension-type headache represents the most prevalent etiology, migraine is the entity with the greatest impact related to disease burden (2,3). Both entities can evolve to chronic daily headache (CDH), which is characterized by reaching a headache frequency equal to or greater than 15 days per month during the last three months (4,5). This syndrome presents a population prevalence of 2.6%, 1.1% for chronic migraine (CM) and 0.5% for chronic tension-type headache (CTTH) (1). In Latin America a prevalence between 5.12 and 7.76 has been reported (6). The CDH group is complemented by hemicrania continua (HC) and new daily persistent headache (NDPH), members of groups III and IV of the International Headache Society (IHS) classification, which represent 0.07% and 1.15%, respectively, in the clinical population (6). Although the IHS classification does not directly consider the concept of CDH, it does define the diagnostic criteria of each of these entities, which allows its application to

clinical practice (table 1). According to the data of disease burden and therapeutic refractoriness of the CDH, this syndrome generates a high impact on the general population, measured in years lived with disability, excessive use of analgesics, decrease in labor production and role restriction (7-9).

Delphi methodology consists of a research technique designed to reach agreements on issues in which there is uncertainty. It is based on the meeting of a group of experts who, by filling out a predetermined questionnaire, provide answers to previously designed questions in search of agreements in related behaviors (10). Its use in health sciences allows obtaining consensus behaviors applicable to clinical practice (11).

The Grade system (Grading of Recommendations Assessment, Development and Evaluation) is a methodology based on a sequential analysis of evidence that determines its quality, its advantages, its disadvantages, direction, and strength of the recommendation obtained from this methodology (12,13).

Taking into account the need to establish therapeutic behaviors for the entities that make up the CDH group, the working group of the Colombian Headache Committee, which is part of the Colombian Association of Neurology (ACN in Spanish), presents the recommendations for the treatment of chronic migraine, chronic tension-type headache, hemicrania continua, and new daily persistent headache.

The thematic components with available evidence through systematic review are presented after the analysis with the Grade methodology, using PICO (patient, intervention, comparison and outcome) ques-

Table 1. Diagnostic criteria based on The International Classification of Headache Disorders 3rd Edition (ICHD 3).

Source: authors

Chronic Migraine	Chronic tension-type headache
A. Headache for a period greater than or equal to 15 days/month for more than three months that meets criteria B and C B. Headache meets criteria B and D for migraine without aura B and C for migraine with aura. C. For a period greater than or equal to eight days/month for more than three months for any of the following: 1. Criteria C and D for migraine without aura 2. Criteria B and C for migraine with aura 3. The patient interprets the pain attacks as migraine and obtains improvement with triptans or ergotic. D. Not attributable to another ICHD 3 diagnosis	A. Headache for a period greater than or equal to 15 days/month for more than three months that meet criteria B-D B. Duration of hours to days, or without remission C. At least two of the following four characteristics: 1. Bilateral location 2. Oppressive pain (non pulsatile) 3. Mild or moderate intensity 4. It does not get worse with physical activity D. The following two characteristics: 1. May associate photophobia, phonophobia or mild nausea (no more than one) 2. No emesis or moderate or severe nausea E. Not attributable to another ICHD 3 diagnosis
Hemicrania continua	New daily persistent headache
A. Unilateral headache meets criteria B-D. B. Duration of more than three months, with exacerbations of at least moderate intensity. C. Any of the following characteristics: 1. At least one of the following signs or symptoms, ipsilateral to the headache: a) Conjunctival hyperemia and/or tearing b) Nasal congestion and/or rhinorrhea c) Palpebral oedema d) Frontal and facial sweating e) Miosis and/or ptosis 2. Feeling restless or agitated, or pain exacerbation with movement D. Response to therapeutic doses of indomethacin E. Not attributable to another ICHD 3 diagnosis	A. Persistent headache that meets criteria B and C B. Unmistakable and clearly remembered onset, with continuous pain without remission for 24 hours C. Present for more than three months D. Not attributable to another ICHD 3 diagnosis

Source: (4).

tions. Those without available evidence are presented through consensus agreements under the Delphi methodology.

METHODOLOGY

The ACN selected the methodological group and the experts that participated in the consensus according to their professional career, academic training, and willingness to participate. The evidence for the generation of the recommendations was selected according to the process described in Figure 1. This evidence was evaluated and integrated into the recommendations through the consensus method. In the questions in which evidence of adequate quality was identified, the generation of recommendations was obtained according to the Grade methodology. The identification of evidence and the consensus method were carried out in the following stages:

Stage 1. Prioritization of topics

The methodological group developed a first list of questions about the treatment of each of the four groups included in the definition of CDH. This list of questions was evaluated by a subgroup of the group of experts who rated the importance of including each question on a seven-point Likert scale (from nothing relevant to totally relevant).

The questions that obtained an interquartile range of 7 to 9 were considered for conducting systematic reviews (15).

After determining the questions related to each topic, the developer group created a search strategy based on the combination of the terms used for the denomination of the different types of chronic daily headache and the filter with the best balance of sensitivity and specificity for the identification of systematic reviews on the OVID platform. In the interventions that required searches for primary studies, no restrictions were used by type of study. All searches were carried out in the OVID version of the Medline, Embase and Cochrane databases and were limited to studies conducted in humans and published in English over the past 20 years (figure 1). Systematic reviews were evaluated by two independent evaluators who rated them using the Amstar methodology; those with a moderate and high evidence score were included in the evidence material considered for this project.

Stage 2. First round of consensus

The methodological group sent a series of preliminary recommendations and their respective tables of evidence individually to each expert via email. Each member was asked to rate their degree of agreement with each proposal, using a seven-point Likert scale. Additionally, each expert had the opportunity to openly write their comments on each preliminary recommendation. Proposals in which an interquartile range of 1 to 3 was obtained were considered as not approved by consensus and those that obtained an interquartile range of 7 to 9 were considered proposals




Figure 1. Results of the systematic review. Source: authors

approved by consensus. The proposals that obtained different interquartile ranges were taken to a second round of qualifications.

Stage 3. Second round of consensus

The proposals that obtained interquartile ranges between 4 and 7 in the first round of the consensus were sent back to each expert via email. Together with these proposals, each participant was sent a tabulation of the results of the qualifications in the first round and the comments made anonymously by the experts. Each of the new proposals from this group was rated individually by each participant. Proposals in which no consensus was obtained in the second round of ratings were taken to consensus through the nominal group method.

Stage 4. Nominal group

For the realization of the nominal group, the thematic leaders of each subgroup (one for each subtype of CDH) met to discuss each of the issues on which no consensus was reached. In this stage, arguments based on experience

and theoretical sources were presented until reaching the consensus of the majority of the participants. At the end of the meeting, the group of experts evaluated the wording of each of the recommendations for inclusion in the final manuscript, including the general principles of the therapeutic approach of the CDH (table 2).

CHRONIC MIGRAINE

1. Is botulinum toxin A (onabotulinum toxin A) effective and safe for the treatment of patients with chronic migraine?

PICO

Population: patients with chronic migraine

Intervention: botulinum toxin (onabotulinum toxin A) 155-195 U

Comparison: placebo

Outcome: headache days/month reduction

Table 2. General principles for the therapeutic approach of patients with CDH. Source: authors.

Comprehensive approach	The approach of patients with chronic daily headache should be a comprehensive one, considering their emotional condition, sleep cycles, body mass index (BMI), individual preferences and other conditions that may affect the clinical prognosis. In all cases, control of the medication overuse should be sought.
Consultation time	The first-time consultation should take 40-60 minutes and the follow-up should take at least 30 minutes.
	Headache diary. It is recommended to indicate a headache diary as a tool for diagnosis and follow-up of all patients with CDH.
Migraine surgery and opioid Prescription	Migraine surgery and prescription of opioid medications are NOT recommended as part of the therapeutic resources for patients with CDH.
Migraine education	Education must be a fundamental part of the strategies used to generate understanding of chronic daily headache and control of risk factors for the disease.
Non-pharmacological Options	Cognitive behavioral therapy, biofeedback, and progressive muscle relaxation.
Therapeutic goals	Although the 50% reduction in headache days is considered as the main therapeutic objective, it is recommended to consider the decrease in pain intensity, the improvement in quality of life, the decrease in consumption of analgesics and improvement in frequency by 30% as part of the therapeutic outcomes.
Treatment duration	There is no evidence that recommends a specific period of treatment duration. The treatment time should be adjusted according to the response of each patient. According to individual outcomes is possible to consider polytherapy including drugs and interventional procedures.

Evidence analysis

Botulinum toxin A – onabotulinum toxin A (ONABOT A) was studied in two randomized controlled clinical trials, PREEMPT 1 and PREEMPT 2. In total, 1384 individuals between 18 and 65 years of age were studied, with a dose of 155-195 u, in 31-39 places of the scalp, compared with placebo and baseline frequency vs. week 24. In PREEMPT 1, the number of headache episodes was analyzed as primary outcome, and there was no statistically significant difference vs. placebo (5.2 vs. 5.3; $p=0.344$). However, secondary outcomes, headache days ($p=0.006$) and migraine days ($p=0.002$) showed a significant reduction compared to placebo (14). In PREEMPT 2 the number of days with headaches was chosen as primary outcome, and superiority of ONABOT A was evidenced vs. placebo (-9.0 vs. -6.7, respectively, $p<0.001$) (15). The secondary outcomes in PREEMPT 2; migraine days frequency, frequency of days of moderate to severe intensity, cumulative monthly hours of migraine, proportion of patients with severe HIT-6 and frequency of headache episodes showed favorable results that support ONABOT A compared to placebo; $p<0.05$ in all cases. Based on the data obtained from the pooled analysis of both studies (16) (onabotulinumtoxin A 47.1% vs. placebo 35.1%; $p<0.001$), an NNT of 8.3 was calculated to achieve 50% improvement. Both studies showed a favorable safety profile, with a low probability of withdrawal due to side effects, NNH: 38. These findings were confirmed in a pooled analysis that showed a decrease in the incidence of adverse effects when comparing cycle 1 with 5 (17). In the long-term follow-up, the COMPEL study (18) analyzed 716 patients aged between 18 and 76 years and showed a reduction of 9.2 and 10.7 days of headache at week 60 and 108, respectively, $p<0.0001$, from a record of 22 days/ month at baseline. These results match with the 56-week analysis based on the pivotal studies (14).

Clinical considerations

ONABOT A is effective in the treatment of chronic migraine with more evidence when comparing the reduction in headache days/month vs. migraine days/month. Studies show limitations that are represented in the risk of unmasking due to aesthetic effects in treated patients (19).

According to the recommendation of experts, therapy with ONABOT A should be initiated in patients who meet the ICHD 3 criteria for chronic migraine, after at least two medications at a maximum tolerated dose for a period of two months have failed. In those patients without response to the first cycle, the opportunity to perform cycle two and three can be considered, taking into account that the probability of obtaining 50% efficacy is 11.3% and 10.3% for each cycle, respectively (20); individual time and

clinical conditions should be part of the analysis factors when considering this choice. If a responding patient is considered, it is recommended to maintain stable doses and intervals of application every 12 weeks. After the first year it is possible to determine the following cycles at 16 and 20 weeks, respectively, with new adjustments according to the clinical response in each case. According to Grade recommendations, the evidence strongly favors the reduction in headache days and migraine days, with partial evidence in migraine episodes (table 3).

Final Recommendation: ONABOT A is recommended for the treatment of patients with chronic migraine. Quality of evidence for headache days: high, recommendation: strong

2. Are anti CGRP drugs effective and safe to treat patients with chronic migraine?

Evidence analysis

PICO

Population: patients with chronic migraine

Intervention: erenumab 70 and 140 mg

Comparison: placebo

Outcome: migraine days reduction

Evidence analysis

Two clinical trials have proven the efficacy of erenumab in patients with chronic migraine. The first one is a phase 2 study with 667 patients and an average migraine day of 18.2, comparing placebo ($n=286$) vs. erenumab 70 mg ($n=191$), or erenumab 140 mg ($n=190$) with an age range of 18-65 years and a 12-week follow-up. Compared to placebo, erenumab 70 and 140 mg reduced migraine days/month by 2.5 days (-2.5, 95%, CI - 3.5 to -1.4) $p<0.0001$ in both cases. The probability of achieving improvement of 50% or greater was 40%, 41% and 23% in the doses of 70 mg, 140 mg, and placebo, respectively, $p<0.001$ in both cases. The calculated NNT was 5.8 and 5.5 for the doses of 140 and 70 mg, respectively, vs. placebo. Both doses also demonstrated a significant decrease in the number of days using analgesics. In the analysis of cumulative hours of headache per month there was only statistical significance for the dose of 140 mg, $p=0.0296$. The probability of withdrawal due to collateral effects was less than 1% (21).

The second study is part of a subgroup analysis in which the same doses are compared against placebo, using as a primary outcome the proportion of patients with a 50% reduction in the frequency of migraine days/month after 12 months of treatment in patients with failure to more than two medications, more than three, excluding failure to more

than four therapeutic options. In the failure to two or more treatments group, the primary outcome was achieved in 34.7% and 40.8%, at doses 70 and 140 mg, respectively, vs. 17.3% for placebo. In the failure to three or more treatments group, this percentage was reached in 35.6% in doses of 70 mg and 41.3% in doses of 140 mg, vs. 14.2% for the placebo group ($p=0.001$ in all cases, in both doses of each group when compared against placebo). The comparison of both doses against placebo in naïve patients showed no statistically significant differences. The report of side effects was low in both analyzes, with a probability of withdrawal of 1.6% or less in both groups for each dose (22).

In an observational study with 65 patients in real clinical practice, a decrease of 12.2 and 15 migraine days/month was documented at week 4 and 8 when compared with the baseline. The response $\geq 50\%$ was reached in 68.2%, 87.5% for the same periods. The study reported no significant side effects (23).

Final recommendation: erenumab is recommended for the treatment of patients with chronic migraine. Quality of evidence: moderate; recommendation: strong.

PICO

Population: Individuals with chronic migraine

Interventions: Galcanezumab 120 mg + loading dose 240 mg and Galcanezumab 240 mg without loading dose.

Comparison: Placebo.

Outcome: Migraine days per month.

Evidence analysis

A phase III randomized clinical trial with participants between 18 and 65 years of age, with an average of 19,4 migraine days, treated as follows: 240 mg loading dose followed by 120 mg monthly dose ($n:278$); 240 mg monthly dose without loading dose ($n:277$); monthly placebo ($n:558$). Both dosages of Galcanezumab resulted in a higher rate of success in reducing the migraine days per month, as follows: placebo -2,7; 120 mg Galcanezumab -4,8; 240 mg Galcanezumab -4,6 ($p < 0,001$ for each dose relative to placebo). The probability of improving at a 50% rate was calculated to be 15,4% for placebo; 27,6% for 120 mg; and 27,5% for 240 mg (24). The number needed to treat (NNT) calculated for 120 mg and 240 mg vs. placebo stood at 8,2 and 8,3 respectively. Furthermore, this trial evidenced statistically significant differences between the 120 mg and 240 mg doses in the reduction of days with headache, hours without pain and migraine, p under 0,005 in all cases. Quality of Life (QOL) scales and the likelihood of reduced use of analgesics were significant only at the 240 mg dose. There were 6 placebo-related withdrawals

and 5 Galcanezumab-related withdrawals. There were no significant differences in laboratory tests when comparing Galcanezumab vs. placebo (24).

One study compared Galcanezumab vs. placebo in patients with failure to ≥ 2 and reported a reduction of 5.35, 2.77 and 1.01 migraine days per month for the 120mg, 240mg and placebo doses, respectively. A reduction of 5.35, 3.53 and 2.02 at doses of 120 mg, 240 mg and placebo, respectively, was observed in the group of failure to ≥ 1 preventive, with p less than 0.05 in all cases. In the group without previous failure, the difference was statistically significant only at a dose of 240 mg (25). There was a decrease in the number of migraine days per month at month three in patients with therapeutic failure to onabotulinum toxin as follows: -3.91, -5.27, -0.88 for Galcanezumab 120mg, Galcanezumab 240mg, and placebo, respectively (26). Open-phase follow-up in 9 patients with an average of 18.38 ± 3.74 migraine days showed reductions of 5.38 ± 4.92 at weeks 1-4 ($p = 0.001$), 4.75 ± 4.15 at weeks 5-8 ($p = 0.001$), and 3.93 ± 5.45 at weeks 9-12 ($p = 0.014$). There was no statistically significant difference when comparing the migraine days per month 12 weeks after completing the open phase against the last 4 weeks of this phase (27).

Final recommendation: Galcanezumab is recommended as a treatment for patients with chronic migraine. Quality of evidence: moderate; recommendation: strong.

PICO

Population: Individuals with chronic migraine

Interventions: Fremanezumab 225 mg – loading dose 675 mg.

Comparison: Placebo.

Outcome: Headache days per month.

Evidence analysis

A phase 3 clinical trial with 1130 participants suffering from chronic migraine having an average of 13.1 headache days per month was conducted to compare the following: 225 mg subcutaneous injection applied monthly and a loading dose of 675 mg (379); 225 mg subcutaneous injection applied monthly and a loading dose of 675 mg; and placebo (375).

The average reduction of headache days per month when comparing the baseline vs. week 12 was 4.6 ± 0.3 when administering the drug on a monthly basis, 4.6 ± 0.3 when administering the drug in a quarterly basis, and 2.5 ± 0.3 when administering the placebo ($p < 0.001$ in both groups vs. placebo). The difference in days between the monthly dose and the placebo was 1.8, while the difference

Table 3. Grade system, therapeutic options in chronic migraine. Source: authors.

Study	Outcome	Type of study	Comparison	Grade of evidence	Direction	Impact	Comment
(16)	Headache days	CCT	Placebo	● ● ● ●	In favor	Strong	1

Grade onabotulinum toxina A.

Study	Outcome	Type of study	Comparison	Grade of evidence	Direction	Impact	Comment
(21)	Migraine days	ECC	Placebo	● ● ● ●	In favor	Strong	1,4

Grade erenumab

Study	Outcome	Type of study	Comparison	Grade of evidence	Direction	Impact	Comment
	Migraine days	ECC	Placebo	● ● ● ●	In favor	Strong	1,4

Grade galcanezumab

Study	Outcome	Type of study	Comparison	Grade of evidence	Direction	Impact	Comment
	Migraine days	CCT	Placebo	● ● ● ●	In favor	Strong	1,3,4

Grade fremanezumab

Study	Outcome	Type of Study	Comparison	Grade of evidence	Direction	Impact	Comment
(40)(39)	Migraine days	ECC	Placebo	● ● ● ●	In favor	Weak	1,6,7,8

Grade Topiramato

Study	Outcome	Type of study	Comparison	Grado of evidence	Direction	Impact	Comment
(54)	Fives days - rescue	CCT	Placebo, celecoxib	● ● ● ●	Againts	Weak	4, 9
(54)	Mild or no headache days	CCT	Placebo, celecoxib	● ● ● ●	Againts	Weak	4, 9

Grade prednisone

CCT: controlled clinical trial

1. Study sponsored by the pharmaceutical industry
2. Risk of inconsistency
3. Risk of inaccuracy
4. No clarity in the selective outcome report

5. Unclear generation of random sequences
6. Unclear allocation concealment
7. Unclear intervention masking
8. Significant losses to follow-up (> 20 %)
9. No intention-to-treat analysis was carried out

in days between the quarterly dose and placebo was 2.1. A similar result was found when comparing fremanezumab vs. placebo in patients with therapeutic failure to other preventative treatments including onabotulinum toxin (28). Improvement at a rate of 50% was reported to be 38% for the quarterly injection, 41% for the monthly injection, and 18% for the placebo ($p < 0.001$ in both groups vs. placebo) (29). NNT: 5 for the quarterly injection, and NNT: 4.3 for the monthly injection. These differences have been documented from week 1 following the start of treatment with doses of 225 mg ($p: 0.048$) maintaining efficacy in the second and third week up to month 3 ($p: 0.04$, $p: 0.025$ and $p < 0.001$, respectively) (30). This effect is maintained when fremanezumab is part of the adjuvant therapy (31). The analysis of secondary outcomes revealed significant differences in the number of migraine days per month, the number of days using acute treatments, and the disease disability score as measured by the Headache Impact Test (HIT) 6 ($p < 0.001$ in all cases). Serious adverse effects were reported in 2% of patients who received placebo and 1% of those who received fremanezumab. Withdrawal for side effects due to treatment was reported in 3% of patients who received fremanezumab vs. 2% of patients who received a placebo (29).

Final recommendation: fremanezumab is recommended as a treatment for patients with chronic migraine. Quality of evidence: moderate; recommendation: strong

Clinical considerations

The consensus analysis recommends prescribing Erenumab, Galcanezumab or Fremanezumab to patients with chronic migraine following the failure of two first-line drugs at maximum tolerated doses for a minimum period of two months (32). The efficacy analyses in real life mirror those reported in pivotal trials (table 4). In these observations, super-responder rates (70-100%) have been reported in 14 to 18% of cases (33). In case of previous treatment with ONABOT A, it is recommended to apply at least two cycles before considering these therapeutic alternatives.

Although the available results for Eptinezumab revealed statistically significant differences compared to the placebo, the source trials were designed for dose exploration, thus Eptinezumab has not been included as part of the recommendations derived from this consensus (34).

In terms of safety, no significant cardiovascular effects have been reported in phase 2 and 3 clinical trials. These findings are consistent with safety data of Erenumab in individuals with stable angina (35) and high blood pressure in combination with Sumatriptan (36). However, the length

of the observation periods in these trials is not enough to extrapolate conclusions to clinical practice, which is why this type of medication is not recommended for patients with uncontrolled cardiovascular risk factors. Additionally, these drugs are not to be prescribed for pregnant or lactating women or individuals with severe mental disorders (32). Caution should be exercised in patients with rigid rheumatic diseases and in cases of recent bone injury (37). There is still no information on the effect of anti CGRP on the HPA (Hypothalamic pituitary axis) axis, and therefore these drugs are not recommended for individuals who have not reached hormonal maturity (37).

Regarding tolerability, real-life patient follow-up has revealed an incidence of constipation, fatigue, and depression at 6-20%, 4-6% and 3-6%, respectively (33). Erenumab, Galcanezumab and Fremanezumab may be prescribed along with preventive oral medications, although treatment with ONABOT A has been recommended before starting an anti CGRP (32). The complementary mechanism of action (38) along with the increase in efficacy reported without impact on safety could allow this combination in selected cases (33). Based on expert recommendations, this consensus suggests maintaining therapy for 6-12 months. Further recommendations will be considered as clinical developments and new evidence come to light (32).

3. Is topiramate effective and safe for the treatment of patients with chronic migraine?

PICO

Population: patients with chronic migraine

Intervention: topiramate

Comparison: placebo - other interventions Outcome: migraine days/month reduction

Evidence analysis

Two multicenter, randomized, double-blind placebo-controlled trials have shown topiramate's efficacy in the treatment of patients with chronic migraine. The first of these, which took into account 306 individuals (topiramate, $n=153$; placebo, $n=153$), showed a reduction in migraine headache days (topiramate -6.4 vs. placebo -4.7, $p=0.010$) (39). The second study included 59 patients and reported a decrease of 3.5 migraine days/month from a baseline of 15.5 days/month, compared with an increase of 0.2 days/month from 16.4 in the baseline ($p=0.02$), the percentage of patients with 50% improvement was 22% for patients with topiramate and 0% for patients with placebo (40). In both studies, paresthesias were reported as the most frequent side effects.

Table 4. Comparative efficacy preventive treatments in chronic migraine. Source: authors.

Drug	Efficacy 50%	Efficacy Placebo 50%	NNT efficacy 50%	Reference
Onabotulinon Toxina A	47.1%	35.1%	8.3	16
Erenumab 70 mg	40%	23%	5.8	22
Erenumab 140 mg	41%	23%	5.5	
Galcanezumab 120 mg	27.6%	15.4%	8.2	24
Galcanezumab 240 mg	27.5%	15.4%	8.3	
Fremanezumab 225 *	41%	18%	5	28
Fremanezumab 225 **	40%	18%	4.3	
Topiramato	22%	0%	4.5	40

*monthly **quarterly

Clinical considerations

The recommended dose, according to clinical trials, should be 100 mg. This dose is based on the results obtained in the clinical trials in episodic migraine in which a balance of greater efficacy and safety was demonstrated, however, according to the clinical response it is possible to reach 200 mg (41). The results obtained in both clinical trials included patients that presented excessive use of analgesics, a variable in which no significant efficacy was demonstrated when compared with placebo, which may be due to the calculation of power in the sample studied. This factor should be considered relevant in clinical practice in those patients in whom it is not possible to significantly reduce the frequent consumption of analgesics. The efficacy of topiramate has been reported equivalent to that obtained with ONABOT A in the global determination of improvement, headache-free days and MIDAS scores at week 12 of treatment (42), Table 4. Other factors to take into account regarding safety are memory impairment, which occurs more frequently with doses greater than 100 mg, urolithiasis, glaucoma and weight loss (41).

Final recommendation: topiramate is recommended for the treatment of patients with chronic migraine. Quality of the evidence: low; recommendation: weak.

4. What other pharmacological options can be considered as part of preventive treatment in patients with chronic migraine?

Evidence analysis

Amitriptyline: in a dose of 25-50 mg, amitriptyline in an open study showed therapeutic equivalence to ONABOT A 250 UI, in the probability of improvement 50% at frequency, 67.8% vs. 72% ($p=0.78$; $RR=0.94$; $CI=0.11-8$). Nor were

there significant differences in pain intensity and use of analgesics. Weight gain was described in 11.8% of patients treated with ONABOT A vs. 58.3% of those treated with amitriptyline ($p=0.0001$). Drowsiness was reported in 4% of patients with ONABOT A vs. 52.7% of those who received placebo ($p=0.0001$). Constipation occurred in 0% of the ONABOT A group vs. 38.8% of the amitriptyline group (43).

Flunarizine: an open study that compared the efficacy measured in days/month of headache in subjects with and without excessive use of analgesics, showed no differences between patients receiving 10 mg of flunarizine vs. TPM 50 mg during an observation period of eight weeks (-4.9 ± 3.8 vs. -2.3 ± 3.5 ; difference -2.6 , 95%; $CI -4.5$ to -0.6 ; $p=0.012$), respectively. The safety and tolerability profile did not show statistically significant differences between the two groups (44). An open study in 40 patients also showed no statistically significant differences at the fourth month of observation but showed a reduction in days of severe pain by 75% for TPM vs. 70% for flunarizine ($p=0.6236$), in doses of TPM 100 mg vs. 5 mg (45).

Divalproex sodium: the comparison of ONABOT A 100 UI vs. divalproex sodium 500 mg/day in a double dummy design with 59 patients with evaluations at months 1, 3, 6, and 9. In the analysis of the chronic migraine subgroup, no statistically significant intergroup differences were observed in the reduction of the number of migraine days, 50% efficacy rate and disability indices (46).

Naratriptan: in an observational study in patients with refractory chronic migraine with a dose of 2.5 mg twice a day, a reduction in headache frequency was reported after two-month treatment (15.3 days vs. 24.1 days on baseline, $p<0.001$), six months (9.1 days vs. 24.1, $p<0.001$), and after one year (7.3 days vs. 24.1, $p<0.001$) (47).

In a similar study, statistically significant reduction to one month (20.4, $p<0.001$), two months (18.9, $p<0.001$), and three months (19.0, $p<0.001$), with better HIT 6 score in every aspect ($p<0.05$ in all cases) was demonstrated 27.1 days/month after baseline by ITT analysis (48).

Clinical considerations

The data obtained for amitriptyline, flunarizine, and naratriptan are based on open studies, a consideration that limits the probability of generating evidence-based recommendations; however, obtaining therapeutic alternatives prior to the indication of high-cost medications establishes an option of interest in daily clinical practice. Despite the methodological limitations of the observational studies, amitriptyline, flunarizine, and divalproex sodium- valproic acid have similar degrees of efficacy to botulinum toxin A and topiramate; however, the presence of side effects that must be adjusted to the profile of each patient should be considered in order to maintain therapeutic adherence. The indication of naratriptan should only be considered in highly refractory patients. Blood pressure monitoring and informed consent are recommended in all cases and should not be indicated in patients with uncontrolled cardiovascular risk factors.

Final recommendation: amitriptyline, divalproex sodium, and flunarizine are recommended as part of the first-line therapeutic options in chronic migraine or as part of polytherapy. Naratriptan on a daily basis may be a treatment option in highly refractory patients. Consensus.

5. Is prednisolone effective in transitional therapy in chronic migraine and excessive use of analgesics?

PICO

Population: patients with chronic migraine and excessive use of analgesics

Intervention: prednisolone

Comparison: placebo - celecoxib - naratriptan

Outcome: percentage of patients requiring rescue analgesics, percentage of patients with moderate and severe pain hours.

Evidence analysis

Prednisolone. The comparison of prednisolone 100 mg vs. placebo in 20 patients showed significant reduction in headache hours of moderate or severe intensity in the first 72 hours after the withdrawal of analgesics (18.1 vs. 36.7 h, $p=0.031$, and 27.22 vs. 42.67 h, $p=0.05$) (49). A

second randomized, double-blind study carried out in 100 patients used a 60 mg dose of prednisolone, with progressive reduction to day 5, compared with placebo, and calculated the average days of headache, including frequency and intensity. The primary outcomes for each group did not show statistically significant differences (1.48 [CI 1.28-1.68] vs. 1.61 [CI 1.41-1.82]) (50). In a similar analysis, the comparison of 100 mg of prednisolone for five days showed statistically significant differences in the rate of analgesic consumption compared to placebo. This analysis found no differences in the reduction of hours with moderate and high intensity headache attacks (51). Comparison between prednisolone 75 mg with celecoxib 400 mg found reduction in pain intensity favoring celecoxib ($p<0.001$). This same study did not show differences in the reduction in headache frequency and consumption of analgesics ($p=0.115$, $p=0.175$, respectively) (52) (table 3).

Clinical considerations

The pooled analysis comparing prednisolone, celecoxib and placebo does not allow to establish differences about the ratio of hours with moderate and severe headache, and consumption of analgesics. There was a significant difference regarding pain intensity, which favors celecoxib. Although the studies coincide with the time of observation, randomization and similarity in the basic characteristics, there are differences in the outcome reports, loss to follow-up, and co-interventions. The mentioned factors indicate low quality evidence, an aspect that suggests the need for studies with a greater methodological scheme that allow exploring the usefulness of prednisolone, especially aimed at decreasing headache intensity and the need for analgesic consumption. The comparison in open design of prednisolone 60 mg vs. naratriptan showed statistically significant intragroup differences when compared to baseline, in headache frequency and intensity, rebound symptoms, and analgesic consumption ($p<0.05$ in all cases); however, this difference was not determined when performing the intergroup comparison (53) (table 3). There were also no differences found when comparing intra vs extra hospital treatments.

Final recommendation: prednisolone is not recommended for transitional therapy in patients with chronic migraine and with excessive use of analgesics. Evidence quality: moderate for headache rescue cases, low for mild or nonexistent headache days. Recommendation: weak.

CHRONIC TENSION-TYPE HEADACHE

6. What medications are effective and safe in the treatment of patients with chronic tension-type headache?

Amitriptyline

In a placebo-controlled clinical trial, slow-release amitriptyline 75 mg (25 mg the first week, 50 mg the second week, and 75 mg starting from the third week) significantly reduced the average daily duration of headache in patients with chronic tension-type headache between weeks 1 and 6; the effect of amitriptyline began to be significant at week 3 of treatment (55). In a controlled clinical trial with 60-90 mg amitriptyline, 50-75 mg amitriptyline and placebo, no significant differences were found in the headache duration x frequency index or in the 50% reduction in headache intensity during 12 weeks of treatment (56). Amitriptyline was studied with citalopram in a 32-week placebo-controlled crossover clinical trial for chronic tension-type headache prophylaxis without depression. This medication reduced the area under the headache curve by 30%, compared to placebo, with a significant reduction in the frequency and duration of headache (57). In another controlled clinical trial of patients with chronic tension-type headache, 203 patients were assigned to amitriptyline 100 mg or nortriptyline 75 mg, placebo; stress management therapy and placebo; or stress management therapy and antidepressant. The three treatment groups improved, compared to placebo, but the improvement was faster with antidepressant medication than with stress management therapy with a response one month after treatment (58). In a meta-analysis with 387 patients, the amitriptyline group had 6.2 headache days less compared to placebo at week 4, the result was maintained at weeks 8, 12 and 24. Additionally, amitriptyline reduces the amount of analgesics and the headache index, in addition to improving the quality of life, with an evidence quality evaluated as high (59). The most frequent side effects of amitriptyline are dry mouth and drowsiness.

Venlafaxine

The efficacy and safety of venlafaxine was assessed in a controlled clinical trial in the treatment of chronic tension-type headache in patients without anxiety or depression (60). Thirty-four patients were treated daily with venlafaxine XR 150 mg, while 26 patients were provided with placebo for 12 weeks. Venlafaxine was taken once a day after breakfast; the first week they took 75 mg and then the dose was raised to 150 mg. The venlafaxine group showed a significant reduction in the number of headache days (from 14.9 to 11.7 days) compared to the placebo group, which did not decrease headache days (from 13.3 to 14.2). The number of responders (a 50% or more reduction in the headache days) was significantly higher in the venlafaxine group (44%) than in the placebo group (15%); NNT was 3.48. In the venlafaxine group, six patients discontinued treatment due to adverse effects (vomiting, epigastralgia, nausea, loss of

libido/anorgasmia) and none of the patients were reported to withdraw in the placebo group. The NNH for a side effect was 5.58.

Imipramine

In a controlled clinical trial, the efficacy of imipramine 25 mg was evaluated every 12 hours in patients with chronic tension-type headache, compared to transcutaneous electrical nerve stimulation. Imipramine significantly reduces headache intensity, with a score of 6.71 to 2.49 on the visual analog scale, with a significantly better reduction compared to transcutaneous electrical nerve stimulation (61).

The efficacy of mirtazapine in chronic tension-type headache was evaluated in a controlled crossover clinical trial (62). Mirtazapine 15 to 30 mg or placebo was administered, two to three hours before bedtime for eight weeks separated by a two-week wash period. The area under the headache curve (duration x intensity) was 34% lower during treatment with mirtazapine than with placebo in 22 patients who participated for the whole study. During the last four weeks of treatment with mirtazapine, 45% of patients improved the area under the curve by at least 30% compared to placebo. The number of headache days in the four weeks decreased from 28 during the placebo period to 25.5 during the period with mirtazapine. Two patients withdrew during active treatment due to the effects.

Clinical considerations

Despite its high prevalence, there are no clinical trials with a solid methodology to confirm the efficacy of the available medications. In all cases, the diagnosis of chronic migraine with intensity pattern modification should be ruled out before considering chronic tension-type headache. It is recommended to start with the lowest possible dose and raise in accordance with efficacy and tolerability. It is necessary to take into account the profile of cholinergic side effects that significantly limit adherence to treatment.

Final recommendation: amitriptyline, mirtazapine, venlafaxine and imipramine are recommended therapeutic options for the treatment of chronic tension-type headache. Consensus.

HEMICRANIA CONTINUA

7. What medications are indicated for the treatment of patients with hemicrania continua?

Indomethacin

Indomethacin has proven to be an effective medication in the acute and preventive treatment of hemicrania conti-

Table 5. Pharmacological options in the hospital treatment of patients with refractory chronic migraine. Source: authors.

Medication	Dose	Precautions
Ketorolac (81)	30 mg IV every 12-8h	Renal function monitoring, allergic reaction, bleeding
Ketoprofen (82)	100 mg IV every 12 h	IDEM
Metoclopramide (83)	10 mg IV every 12 h	IDEM
Dipyron (77)	1-2g IV every 8-6 h	Anaphylaxis
Methylprednisolone	500 mg IV day	Liver dysfunction
Dexamethasone (85)	8 mg IV every 12-8h	Gastritis, nausea
Divalproex sodium (86)	300-1200 mg IV	Nausea, sedation, vertigo
Haloperidol (87)	1,25 mg IV every 12 h*	Dyskinesia, parkinsonism, hypotension, torsade de pointes. ECG must be carried out before starting treatment
Magnesium sulphate (88)	1-2 g IV	Indicated in migraine with aura. Monitor the appearance of muscle weakness, hypotension and respiratory depression
Propofol (85)	10 mg boluses every 10 min. Maximum dose of 80 mg	Infusion should be indicated at intensive care unit due to the risk of apnea, sedation and hypotension. The probability of dependency development should be considered.

* The recommended dose is lower than that used in clinical trials, in order to reduce the likelihood of side effects.

nua, even since the initial reports (63,64). This efficacy has been demonstrated with doses between 25-150 mg/day with total symptom control after 72 hours of treatment initiation (65,66).

In a cohort of 36 patients, 33 with criteria for HC who received placebo and indomethacin at different times achieved total pain control in 89% of the cases when they were exposed to the medication (average dose 176 mg/ day, with a minimum of 25 and maximum of 500 mg/ day). None of the patients in the placebo group achieved improvement (67). Another series of 36 patients exposed to oral indomethacin test with a maximum dose of 250 mg/day reported pain control in all patients; however, poor tolerance to high doses of the molecule was described (68). In a retrospective case series, three out of ten patients diagnosed with hemicrania continua reported efficacy in doses of 50-300 mg with limited gastrointestinal tolerability in all cases (69).

In a series of 26 patients with an average dose of 75 mg, 16 with a diagnosis of hemicrania continua, 3.8 years were followed up, and improvement was reported within the first three days of treatment. During follow-up, 42% of patients maintained clinical control, which allowed the dose to be reduced up to 60% (66).

Melatonin

In 2006, the case of a 42-year-old patient was reported, with HC and indomethacin intolerance (but with complete

response to it), who achieved total pain control with the use of 7 mg of melatonin during the 5-month-follow-up time (70). Subsequently, three women with indomethacin intolerance used melatonin in ascending dose every fifth day, starting with 3 mg to achieve total pain control (maximum allowed 24 mg/day), two of them at 9 mg and the third at 15 mg reported total pain control; in cases of pain attack, control was reported with 6 mg rescue dose (71).

In 2013, the case of a 60-year-old patient with a response to indomethacin was reported, but with limited tolerability, in which the administration of melatonin 9 mg/day produced complete pain control (72). The largest case series presented the retrospective analysis of 11 patients (nine women, two men). Of these, six showed no response to the use of melatonin in doses of 9-27 mg/day, two achieved total pain control at low doses of 3-6 mg/day, while the remaining three obtained only partial control, which allowed the decrease of the daily dose of this medicine (73).

Topiramate

In 2006, two cases were reported with hemicrania continua and a positive response to indomethacin, but with adherence limitations due to non-tolerability. Both patients, who received topiramate between 100 and 200 mg/day, being intolerant as well though, achieved pain control similar to that obtained with indomethacin (74). Afterwards, based on the previous reference, two similar

cases were reported with indomethacin intolerance due to gastrointestinal effects. After the start of topiramate at 150-200 mg/day, sustained pain control was achieved after six and eight months of treatment suspension (75). Recently, pain control was reported in two patients, combining indomethacin 75 mg/day and topiramate 50 to 75 mg/day, given the non-tolerance at higher doses in one or both molecules, which shows synergy between them and total pain control (76).

Celecoxib

In a series of 14 patients, nine with rofecoxib and five with celecoxib, the latter group, in weekly ascending dose up to a maximum of 800 mg/day, produced total or partial response in 80% of cases (77). In a report of four patients with hemicrania continua and indomethacin intolerance, total pain control was documented in doses ranging from 200-400 mg/day and with persistence of the clinical effect to the continuous use of the molecule in a range of 6 to 18 months later (78).

Clinical considerations

Indomethacin, in doses of 25 up to 250 mg per day, is considered the medication of choice; its efficacy is diagnostic criteria in HC (4). However, there are cases in which there is no efficacy, or this is limited to aspects of tolerability and safety. In this type of cases it is possible to consider the use of melatonin 3-30 mg/day, topiramate 75-200 mg/day or celecoxib 200-400 mg/day in joint or replacement therapy. Prior to this consideration, the addition of sodium, potassium or misoprostol-type prostaglandin pump inhibitors may improve indomethacin tolerance. The cardiovascular risk profile associated with celecoxib should be considered.

Final recommendation: indomethacin is the medication of choice for patients with hemicrania continua. In cases of non-efficacy or non-tolerability, the use of melatonin, celecoxib or topiramate is recommended in addition or replacement therapy. Consensus

NEW DAILY PERSISTENT HEADACHE

8. What pharmacological options can be effective in the treatment of patients with new daily persistent headache?

Gabapentin

Gabapentin, in doses of 1800 and 2700 mg per day has reported efficacy in series of patients with new daily persistent headache (79,80); the main adverse effects include sedation, ataxia and fatigue.

Doxycycline

In an open study that included four patients with new daily persistent headache and elevated tumor necrosis factor in the open CSF, doxycycline was used at a dose of 100 mg every 12 hours for three months; at two months of treatment, partial or total improvement was reported; the main adverse effects were nausea, vomiting and epigastralgia (80).

Clinical considerations

The low prevalence of new daily persistent headache makes it difficult to obtain information based on studies that provide evidence for the treatment of this medical condition. The therapeutic response is limited and, probably, the resolution of symptoms is explained by the disease's own remission, rather than the effect provided by the pharmacological agents. Two disease phenotypes have been described, one similar to migraine and the second to tension-type headache. According to each of them it is possible to choose approved pharmacological options for each of these entities.

Final recommendation: despite the limited evidence, the use of gabapentin and/or doxycycline is recommended as treatment options for new daily persistent headache. Consensus.

COMPLEMENTARY INTERVENTIONS

9. When should hospitalization be considered in patients with chronic migraine?

Clinical considerations

It is recommended in patients without response to outpatient treatment despite optimal doses of acute and preventive medications, presence of comorbidities that limit adherence to therapeutic indications and excessive use of opioids. This procedure is justified by the use of parenteral medications and comprehensive assessment including psychiatry, neuropsychology, nutrition and other specialties considered according to the basic profile of each patient (11). The recommended options in hospital treatment vary according to the comorbidities of each patient and the options available in each institution (table 4).

10. What procedures are indicated in the treatment of patients with chronic daily headache?

Nerve blocks

CDH is included as one of the indications for the pericranial nerve blockade (89). In chronic migraine, efficacy has been described in a study of 36 patients who compared

bupivacaine infiltrations of the occipital nerve vs placebo. This study showed a significant reduction in the frequency, intensity and duration of headache episodes compared to baseline and placebo (90). A second study, with 44 patients, showed similar results also comparing placebo vs. bupivacaine (91). According to observations in real clinical practice, the efficacy of this type of intervention starts minutes after infiltration (92).

The sphenopalatine ganglion block has also shown a significant reduction in the numerical pain scale compared to placebo in patients with chronic migraine in measurements at 15, 30 minutes and 24 hours, after irrigation of the ganglion with bupivacaine. This difference between placebo and treatment was not reached after months 1 and 6, despite the difference in the numerical scale compared to the baseline (93). In a series of cases with hemicrania continua composed of 36 patients (28 women, 8 men), 13 were operated for non-tolerance to indomethacin with block 1:1 mixture of bupivacaine/mepivacaine. Of this group, 7/13 obtained total pain control, 5/13 got a decrease of three points in pain scale, and one had no response; the therapeutic effect lasted an average of three months (68).

In a prospective series of 22 patients with hemicrania continua, nine cases of indomethacin intolerance were intervened with greater occipital and supraorbital nerve blockade, with 1:1 mixture of bupivacaine/mepivacaine; in the cases of trochlear block 4 mg of triamcinolone were injected. Regarding the presence of pain in the point exploration, 5/9 patients obtained total pain control and 4/5 partial control. The duration of the most frequent analgesic effect was three months (94). Sphenopalatine ganglion block was reported effective in a patient with hemicrania continua, intolerant to indomethacin, topiramate and no response to melatonin. After ipsilateral irrigations with bupivacaine 0.5%, twice a week for 6 weeks, through Tx360® and injecting from week 6, total pain control was achieved, and subsequently control blockades were made every four to five weeks (95).

Several retrospective case series with a small number of patients with new daily persistent headache (3-23 patients, 57 patients in total) were treated with bupivacaine and methylprednisolone, or lidocaine and methylprednisolone blockade, in different nerves, and it was the greater occipital nerve the most frequently operated. These reports described a response rate of 33.3 to 66% with a response duration of one day to 5.4 weeks (73,89-92).

Clinical considerations

Nerve blocks seek to control the phenomenon of pericranial hypersensitivity common to several subtypes of headaches, including those of the primary type, and the entities that make up the CDH. Although most of the reports are

described with bupivacaine, it is possible to use lidocaine in equivalent doses to 1-2 ml per point in the occipital region and 0.1-0.3 ml in the temporal region and facial points. Its use is safe in pregnant women and a short-term clinical effect is expected, which can be useful in the transition of the effect of the chosen preventive medications and in the detoxification due to excessive use of analgesics.

CONCLUSION

The recommendations generated for the preventive treatment of chronic migraine, chronic tension-type headache, hemicrania continua, and new daily persistent headache coincide with the concepts contained in similar documents published by other scientific societies, with modifications adjusted to the population (32).

Regarding the limited availability of evidence in most of the recommended molecules, the consensus methodology complements the information obtained through systematic review and Grade methodology.

This strategy increases treatment alternatives prior to indication of high-cost therapies, which allows economic factors to be considered alongside clinical decisions. This document must be modified within five years, based on the guidelines of the ACN headache group and the need for incorporation of new sources of scientific evidence.

Acknowledgment

To the Asociación Colombiana de Neurología, Research group on Neurology - Hospital MEDERI and Group of Neurology Clínica Colombia for the financial support for this project, also to those who believe in the value of academic publications as a simple manner to lift individuals out of underdevelopment.

Conflict of interest

Fidel Sobrino, Michel Volcy, Juan Diego Jiménez, Joe Muñoz, Michel Volcy, Sergio Ramírez, Oscar Pradilla, Natalia Hernández, Marta Ramos and José D Martínez has served as speakers or consultants for Novartis Colombia.

Fidel Sobrino, Michel Volcy, Juan Diego Jiménez, Joe Muñoz, Michel Volcy, Sergio Ramírez, Oscar Pradilla, Natalia Hernández, Marta Ramos and Carolina Guerra has served as speakers or consultants for Novartis Colombia.

Michel Volcy and Fidel Sobrino has served as consultants for Allergan before INVIMA

Michel Volcy and Joe Muñoz have provided services as consultants for Novartis before INVIMA

Joe Muñoz, Michel Volcy, Fidel Sobrino, Sergio Ramírez, Bernardo Uribe, Oscar Pradilla has served as consultants for Lilly Colombia.

REFERENCIAS

- Schramm SH, Obermann M, Katsarava Z, Diener H-C, Moebus S, Yoon M-S. Epidemiological profiles of patients with chronic migraine and chronic tension-type headache. *J Headache Pain* [Internet]. 2013;14:2-8
- Allena M, Steiner TJ, Sances G, Carugno B, Balsamo F, Nappi G, et al. Impact of headache disorders in Italy and the public-health and policy implications : a population-based study within the Eurolight Project. *J Headache Pain* . 2015; 100:2-9
- Stovner IJ, Andree C. Prevalence of headache in Europe: A review for the Eurolight project. *J Headache Pain*. 2010;11:289–99.
- Vincent M, Wang S. The International Classification of Headache Disorders , 3rd edition. *Cephalalgia*. 2018;38:1–211.
- Rodrigo A, Giacomozzi E, Vindas AP, Alberto A, Bordini A, Buonanno CF, et al. Latin American consensus on guidelines for chronic migraine treatment. *Arch Neurops*. 2013;71:478–86.
- Lupi C, Evangelista L, Favoni V, Granato A, Negro A, Pellesi L, et al. Rare primary headaches in Italian tertiary Headache Centres : Three year nationwide retrospective data from the RegisRare Network. *Cephalalgia*. 2018;0(0):1–13.
- Smitherman TA, Burch R, Sheikh H, Loder E. The prevalence, impact, and treatment of migraine and severe headaches in the United States: A review of statistics from national surveillance studies. *Headache*. 2013;53:427–36.
- Adams AM, Serrano D, Buse DC, Reed ML, Marske V, Fanning KM, et al. The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results. *Cephalalgia*. 2015;35(7):563–78.
- Buse DC, Manack a, Serrano D, Turkel C, Lipton RB. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. *J Neurol Neurosurg Psychiatry* [Internet]. 2010;81:428–32.
- Fernández-Ávila DG, Rojas MX .El método Delphi en la investigación en reumatología: Lo estamos haciendo bien? *Rev Colomb Reumatol*. 2020;27(3):177-89.
- Muñoz J, Volcy M, Sobrino F, Ramírez S, Uribe B. et al. Consenso de expertos de la Asociación Colombiana de Neurología para el tratamiento preventivo y agudo de la migraña. *Acta Neurol Colomb*. 2014;30(3):175-85.
- Leone MA, Brainin M, Boon P, Pugliatti M, Keindl M, Bassetti CL. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces – revised recommendations *Eur J Neurol*. 2012. 2013;410–9.
- Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2 : a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions , or both. *BMJ* 2017;358:1–9.
- Aurora SK, Dodick DW, Diener H-C, DeGryse RE, Turkel CC, Lipton RB, et al. OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program. *Acta Neurol Scand* [Internet]. 2014;129:61–70.
- Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. *Cephalalgia*. 2010;30:804–14.
- Dodick DW, Turkel CC, Degryse RE, Aurora SK, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for Treatment of Chronic Migraine : Pooled Results From the Double-Blind , Randomized , Placebo-Controlled Phases of the PREEMPT Clinical Program. *Headache*.2010; 50:921-36
- Diener H-C, Dodick DW, Turkel CC, Demos G, Degryse RE, Earl NL, et al. Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine. *Eur J Neurol*. 2014;21:851–9.
- Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Adams AM. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine : COMPEL study. *J Headache Pain*. 2018; 19:1-13
- Herd CP, Tomlinson CL, Rick C, Scotton WJ , Edwards J, Ives N, et al. Botulinum toxins for the prevention of migraine in adults (Review). *Cochranedata base Syst Rev*. 2018;(6). CD011616.
- Silberstein SD, Dodick DW, Aurora SK, Diener H, Degryse RE, Lipton RB, et al. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle : PREEMPT. *J Neurol Neurosurg Psychiatry* 2015;86: 996-1001
- Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S, et al. Articles Safety and efficacy of erenumab for preventive treatment of chronic migraine : a randomised , double-blind , placebo-controlled phase 2 trial. *Lancet Neurol*. 2017; 16:425-434
- Ashina M, Tepper S, Brandes JL, Reuter U, Boudreau G, Dolezil D, et al. Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure : A subgroup analysis of a randomized , double-blind , placebo-controlled study. *Cephalalgia*.2018;0:1–11.
- Barbanti P, Aurilia C, Egeo G, Fofi L. Erenumab : from scientific evidence to clinical practice — the first Italian real-life data. *Neurol Sci*. 2019;40:177-179
- Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine. *Neurology*.2018;0:2211–21.
- Ruff DD, Ford JH, Tockhorn-heidenreich A, Sexson M, Govindan S, Pearlman EM, et al. Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure. *Cephalalgia*.2019;39:931–44.
- Ailani J, Perlman D, Zhang Q, Nagy A, Schuh K. Aurora S. Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: Post hoc analyses of 3 randomized double-blind studies. *Europ J Neurol*. 2020; 27(3):542-9.
- Raffaelli B, Mussetto V, Israel H, Neeb L, Reuter U. Erenumab and galcanezumab in chronic migraine prevention : effects after treatment termination. *J Headache Pain*. 2019;20:1-5
- Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R, et al. Articles Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised , double-blind , placebo-controlled , phase 3b trial. *Lancet*. 2019;6736:1–11
- Goadsby PJ, Ph D, Blankenbiller T, Wolff MG, Yang R, Ph D, et al. Fremanezumab for the Preventive Treatment of Chronic

- Migraine. *N Eng J Med*. 2017;2113–22.
30. Bigal ME, Dodick DW, Aboch V, Vanderpluym JH, Tepper SJ, Aycardi E, et al. TEV-48125 for the preventive treatment of chronic migraine Efficacy at early time points. *Neurology*. 2016;0:41–8.
31. Cohen JM, Dodick DW, Yang R, Newman LC, Li T, Aycardi E, et al. Research Submission With Other Migraine Preventive Medicines. *Headache*. 2017;57(9):1375-1384
32. Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas D, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. *J Headache Pain*. 2019 16;20:6
33. Robbins, L. Special report: CGRP monoclonal antibodies for chronic migraine. *Pract Pain Manag* 2019;19:45–52.
34. Dodick DW, Lipton RB, Silberstein S, Goadsby PJ, Biondi D, Hirman J, et al. Eptinezumab for prevention of chronic migraine : A randomized phase 2b clinical trial. *Cephalalgia*. 2019;39:1075–85.
35. Depre C, Antalík L, Starling A, Koren M, Eisele O, Lenz R, A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina. *Headache*. 2018; 58:715-723
36. Hoon J De, Hecken A Van, Vandermeulen C, Herbots M, Kubo Y, Lee E, et al. to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers. *Cephalalgia*. 2018;0(0):100–110.
37. Robbins BL. At Stake : The Possible Long-Term Side Effects of CGRP Antagonists. *Practical Pain Management*. 2018 :1–10.
38. Melo-carrillo A, Strassman AM, Nir R, Schain XJ, Nosedá XR, Stratton XJ, et al. Fremanezumab — A Humanized Monoclonal Anti-CGRP Antibody — Inhibits Thinly Myelinated (A δ) But Not Unmyelinated (C) Meningeal Nociceptors. *J Neurosci*. 2017;37:10587–96.
39. Silberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N, Brandes JL, Bigal M, Greenberg D. Efficacy and Safety of Topiramate for the Treatment of Chronic Migraine : A Randomized, Double-Blind , *Headache*. 2007;170–80.
40. Diener H-C, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. *Cephalalgia*. 2007;27:814–23.
41. Silberstein SD. Topiramate in Migraine Prevention : A 2016 Perspective. *Headache*. 2016;57:165–178.
42. Cady RK, Schreiber CP, Porter J a H, Blumenfeld AM, Farmer KU. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. *Headache*. 2011;51:21–32.
43. Magalhães E, Menezes C, Cardeal M, Melo A. Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine. *Clin Neurol Neurosurg*. 2010;112:463–6.
44. Lai K, Fuh DMNJ, Chen S, Wang Y, Chen W, Wu J, et al. Flunarizine versus topiramate for chronic migraine prophylaxis : a randomized trial. *Pain Med*. 2016;13:1–8.
45. Gracia-naya M, Ríos C, García-gomara MJ, Sánchez-valiente S, Mauri-llerda JÁ, Santos-lasaosa S, et al. Estudio comparativo de la efectividad del topiramato y la flunaricina en series independientes de pacientes con migraña crónica sin abuso de medicación. *Rev Neurol*. 2013;57:347–53.
46. Blumenfeld AM, Schim JD, Chippendale TJ. Research Submission Botulinum Toxin Type A and Divalproex Sodium for Prophylactic Treatment of Episodic or Chronic Migraine. *Headache*. 2007;48:210–20.
47. Rapoport AM, Bigal ME, Volcy M, Sheftell FD, Feleppa M, Tepper SJ. Brief Communication Naratriptan in the Preventive Treatment of Refractory Chronic Migraine : A Review of 27 Cases. *Headache*. 2003;482–9.
48. Sheftell FD, Rapoport AM, Tepper SJ, Bigal ME. Naratriptan in the Preventive Treatment of Refractory Transformed Migraine : A Prospective Pilot Study. *Headache*. 2005;45:1400–6.
49. Pageler L, Katsarava Z, Diener HC, Limmroth V. Prednisone vs. placebo in withdrawal therapy following medication overuse headache. *Cephalalgia*. 2008;28:152–6.
50. Bøe MG, Mygland A, Salvendy R. Prednisolone does not reduce withdrawal headache. *Neurology*. 2007;69:26–32.
51. Rabe K, Pageler L, Gaul C, Kraya T, Foerderreuther S, Diener H, et al. Prednisone for the treatment of withdrawal headache in patients with medication overuse headache : A randomized , double-blind , placebo-controlled study. *Cephalalgia*. 2012;33:202–7.
52. Taghdiri F, Togha M, Jahromi SR, Paknejad SMH. Celecoxib vs prednisone for the treatment of withdrawal headache in patients with medication overuse headache: a randomized, double-blind clinical trial. *Headache*. 2015;55(1):128-35.
53. Krymchantowski A V, Moreira PF. Out-patient detoxification in chronic migraine : comparison of strategies. *Cephalalgia*. 2003;982–93.
54. Goffau MJ De, Klaver ARE, Willemsen MG, Bindels PJE, Verhagen AP. The effectiveness of treatments for patients with medication overuse headache; a systematic review and meta-analysis. *J Pain*. 2017; 8:615-627
55. Gobel H, Hamouz V, Hansen C, Heininger K, Hirsch S, Lindner V, et al. Chronic tension-type headache : amitriptyline reduces clinical headache-duration and experimental pain sensitivity ~ but does not alter pericranial muscle activity readings. *Pain*. 1994;59:241–9.
56. Pfaffenrath V, Diener H, Isler H, Meyer C, Scholz E, Taneri Z, et al. Efficacy and tolerability of amitriptylinexide in the treatment of chronic tension-type headache : a multi-centre controlled study. *Cephalalgia*. 1994;14:8–14.
57. Bendtsen L, Jensen R, Olesen J. A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. *J Neurol Neurosurg Psychiatry*. 1996;61:285–90.
58. Holroyd KA, Donnell FJO, Stensland M, Lipchik GL, Cordingley GE, Page P. Management of Chronic Tension-Type. *JAMA*. 2001;285(17):2208–15.
59. Jackson JL, Mancuso JM, Nickoloff S, Bernstein R, Kay C. Tricyclic and Tetracyclic Antidepressants for the Prevention of Frequent Episodic or Chronic Tension-Type Headache in Adults : A Systematic Review and Meta-Analysis. *J Gen Int Med*. 2017;1351–8.
60. Zisis NP, Harmoussi S, Vlaikidis N, Mitsikostas D, Thomaidis T, Georgiadis G, et al. A randomized , double-blind , placebo-controlled study of venlafaxine XR in out-patients with tension-type headache. *Cephalalgia*. 2007;(8):315–24.
61. Mousavi Sayed Ali, Mousavi Mohossen FK. Comparison between efficacy of imipramine and transcutaneous electrical nerve stimulation in the prophylaxis of chronic tension-type headache: a randomized controlled clinical trial. *J Res Med Sci*. 2011;16:923–7.

62. Bendtsen L, Buchgreitz L, Ashina S, Jensen R. Combination of low-dose mirtazapine and ibuprofen for prophylaxis of chronic tension-type headache. *Eur J Neurol*. 2007;187–93.
63. Sjaastad O. Evidence For A New ?, Treatable Headache Entity. *Headache*. 1972;14:105–108.
64. Sjaastad O, Spierings ELH. “Hemicrania continua”: another headache absolutely responsive to indomethacin. *Cephalalgia*. 1984; 4:65–70
65. Pareja JA, Sjaastad O. Chronic Paroxysmal Hemicrania and Hemicrania Continua. Interval Between Indomethacin Administration and Response. *Headache*. 1996;8–20–3
66. Rõ A, Pareja JA, Caminero AB, Franco E, Casado JL, Pascual J, et al. Dose, efficacy and tolerability of long-term indomethacin treatment of chronic paroxysmal hemicrania and hemicrania continua. *Cephalalgia*. 2001;(3):906–10.
67. Cittadini E, Goadsby PJ. Hemicrania continua: a clinical study of 39 patients with diagnostic implications. *Brain*. 2010;133:1973–86.
68. Cortijo E, Guerrero-peral ÁL, Herrero-velázquez S, Mulero P, Pedraza M, Barón J, et al. Hemicránea continua : características y experiencia terapéutica en una serie de 36 pacientes. *Neurología*. 2012;55(5):270–8.
69. Maria L, Rocha V, Marcelo J, Bezerra F, Regina N, Fleming P. Tratamiento de la Hemicránea Continua : Serie de Casos y Revisión de la Literatura. *Rev Bras Anestesiol*. 2012;62:173–187.
70. Spears R. Hemicrania Continua: A Case in Which A Patient Experienced Complete Relief on Melatonin. *Headache*. 2006;46: 524–27
71. Rozen TD. Melatonin Responsive Hemicrania Continua. *Headache*. 2006;46:1203–9.
72. Hollingworth M, Young TM. Melatonin Responsive Hemicrania Continua in Which Indomethacin Was Associated With Contralateral Headache. 2014;54: 916–9
73. Rozen TD. How Effective Is Melatonin as a Preventive Treatment for Hemicrania Continua ? A Clinic-Based Study. *Headache*. 2015;55:430–6.
74. Matharu MS, Bradbury P, Swash M. Hemicrania continua : side alternation and response to topiramate. *Cephalalgia*. 2005; 26:341–344
75. Brighina F, Palermo A, Cosentino G, Fierro B. Prophylaxis of hemicrania continua: Two new cases effectively treated with topiramate. *Headache*. 2007;47:441–43.
76. Prakash S, Rana K. Clinical Correspondence Topiramate as an Indomethacin-Sparing Agent in Hemicrania Continua : A Report of 2 Cases. *Headache*. 2019;59:1–2.
77. Peres M, Silberstein SD. Hemicrania Continua Responds to Cyclooxygenase-2 Inhibitors. *Headache*. 2002;530–1.
78. Porta-Etessam J, Cuadrado P, Valencia C. Are Cox-2 drugs the second line option in indomethacin responsive headaches ? *J Headache Pain*. 2010;405–7.
79. Nierenburg H, Newman LC. Update on New Daily Persistent Headache. *Curr Treat Options Neurol* . 2016; 18:25
80. Rozen TD. New Daily Persistent Headache : An Update. *Curr Pain Headache Rep*. 2014; 18:431
81. Taggart E, Doran S, Kokotillo A, Campbell S, Villa-Roel C, Rowe BH. Ketorolac in the treatment of acute migraine: a systematic review. *Headache*. 2013;53:277–87.
82. Domi R. The intravenous administration of ketoprofene : a suitable alternative for acute postoperative pain management in developing countries. *Clin J Pain*. 2004;20(3):198.
83. Friedman BW, Garber L, Yoon A, Solorzano C, Wollowitz A, Esses D, et al. Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine. *Neurology* . 2014;82:976–83.
84. Ramanioccti As, Soares B, Atallah A. Dipyron for acute primary headaches (Review). *Cochrane Database Syst Rev* 2014;(7). CD004842.
85. Soleimanpour H, Rajaei Ghafouri R, Taheraghdam A, Aghamohammadi D, Negargar S, Golzari SE, et al. Effectiveness of intravenous Dexamethasone versus propofol for pain relief in the migraine headache: a prospective double blind randomized clinical trial. *BMC Neurol*. 2012;12:2–7
86. Foroughipour M, Ghandehari K, Khazaei M, Ahmadi F, Shariatinezhad K. Randomized clinical trial of intravenous valproate (orifil) and dexamethasone in patients with migraine disorder. *Iran J MedSci*. 2013;38:150–5.
87. Kelley NE, Tepper DE. Rescue therapy for acute migraine, part 2: neuroleptics, antihistamines, and others. *Headache*. 2012;52:292–306.
88. Kelley NE, Tepper DE. Rescue therapy for acute migraine, part 1: triptans, dihydroergotamine, and magnesium. *Headache* . 2012;52:114–28.
89. Blumenfeld A, Ashkenazi A, Napchan U, Bender SD, Klein BC, Berliner R, et al. Expert consensus recommendations for the performance of peripheral nerve blocks for headaches--a narrative review. *Headache*. 2013;53:437–46.
90. Hascalovici JR, Robbins MS. Research Submission Peripheral Nerve Blocks for the Treatment of Headache in Older Adults : A Retrospective Study. *Headache*. 2017;57:80–6.
91. Gul HL, Ozon AO, Karadas O, Koc G, Inan LE. The efficacy of greater occipital nerve blockade in chronic migraine : A placebo- controlled study. *Acta Neurol Scand*. 2016;136:1–7.
92. Young W, Cook B, Malik S, Shaw J, Oshinski M. The First 5 Minutes After Greater Occipital Nerve Block Headache. 2014;48(7):1126–8.
93. Cady RK, Saper J, Dexter K, Cady RJ, Manley HR. Randomized Study for Repetitive Sphenopalatine Blockade With Bupivacaine vs Saline With the Tx360 ® Device for Treatment of Chronic Migraine. *Headache*. 2015; 55:101–116
94. Guerrero L, Herrero-vela S, Pen L, Pedraza I, Cortijo E, Mulero P, et al. Peripheral nerve blocks : a therapeutic alternative for hemicrania continua. *J Headache Pain*. 2012;32(6):505–8.
95. Androulakis XM, Krebs KA, Ashkenazi A. Hemicrania continua may respond to repetitive sphenopalatine ganglion block: A case report *Headache* . 2016; 56:573–579